Eligible covered entities in Georgia may enroll in the 340B program immediately, rather than having to wait for the next [...] …
Category: Providers
Drug manufacturer Jazz Pharmaceuticals this week became the 25th drug manufacturer to impose conditions on 340B pricing involving delivery to contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Sanofi recently started denying access for some health centers to 340B pricing at contract pharmacies after previously saying [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The California Senate recently cleared a bill to bar pharmacy benefit manager (PBM) alleged discrimination against 340B covered entities and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Merck recently announced that it owes refunds to 340B covered entities for purchases of 17 products during the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Inaccurate points were ascribed to 340B advisers and service providers in a recent legal filing by four drugmakers as part [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eligible covered entities in Florida may enroll in the 340B program immediately rather than having to wait for the next [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
While federal regulators recently extended the comment period on a proposed lump sum repayment plan for hospitals Illegally underpaid for [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Draft legislation that would exclude some generics from 340B and focus on penny pricing recently drew criticism from provider advocates. [...] …